Towards reliable diagnostics of prostate cancer via breath.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 09 2021
15 09 2021
Historique:
received:
14
05
2021
accepted:
17
08
2021
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
17
12
2021
Statut:
epublish
Résumé
Early detection of cancer is a key ingredient for saving many lives. Unfortunately, cancers of the urogenital system are difficult to detect at early stage. The existing noninvasive diagnostics of prostate cancer (PCa) suffer from low accuracy (< 70%) even at advanced stages. In an attempt to improve the accuracy, a small breath study of 63 volunteers representing three groups: (1) of 19 healthy, (2) 28 with PCa, (3) with 8 kidney cancer (KC) and 8 bladder cancer (BC) was performed. Ultrabroadband mid-infrared Fourier absorption spectroscopy revealed eight spectral ranges (SRs) that differentiate the groups. The resulting accuracies of supervised analyses exceeded 95% for four SRs in distinguishing (1) vs (2), three for (1) vs (3) and four SRs for (1) vs (2) + (3). The SRs were then attributed to volatile metabolites. Their origin and involvement in urogenital carcinogenesis are discussed.
Identifiants
pubmed: 34526529
doi: 10.1038/s41598-021-96845-z
pii: 10.1038/s41598-021-96845-z
pmc: PMC8443711
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18381Informations de copyright
© 2021. The Author(s).
Références
Medicine (Baltimore). 2018 Mar;97(13):e0249
pubmed: 29595681
Molecules. 2020 Apr 09;25(7):
pubmed: 32283766
Nat Commun. 2019 Dec 4;10(1):5521
pubmed: 31797927
Front Immunol. 2015 Nov 03;6:554
pubmed: 26579129
Comput Biol Med. 2018 May 1;96:227-232
pubmed: 29653351
J Cancer. 2019 Jul 8;10(17):4038-4044
pubmed: 31417648
Lancet. 2003 Mar 8;361(9360):859-64
pubmed: 12642065
Sci Rep. 2019 Nov 7;9(1):16167
pubmed: 31700057
Int J Clin Exp Med. 2015 Feb 15;8(2):2562-9
pubmed: 25932202
Oncotarget. 2018 May 18;9(38):24882-24897
pubmed: 29861840
Sci Immunol. 2016 Oct 28;1(4):
pubmed: 28783689
J Urol. 2015 Apr;193(4):1382-7
pubmed: 25264338
J Immunol. 2019 Mar 15;202(6):1767-1776
pubmed: 30737272
Oncotarget. 2017 Jul 11;8(51):89315-89325
pubmed: 29179522
Nature. 2020 Jan;577(7788):52-59
pubmed: 31894146
J Breath Res. 2014 Mar;8(1):014001
pubmed: 24421258
Am J Ind Med. 1998 Mar;33(3):293-6
pubmed: 9481428
Metabolites. 2014 Jun 20;4(2):465-98
pubmed: 24957037
Investig Clin Urol. 2016 Jun;57 Suppl 1:S77-88
pubmed: 27326410
ACS Nano. 2017 Jan 24;11(1):112-125
pubmed: 28000444
PLoS One. 2015 Nov 24;10(11):e0143283
pubmed: 26599280
Br J Cancer. 2019 Nov;121(10):857-868
pubmed: 31588123
Future Oncol. 2006 Apr;2(2):225-32
pubmed: 16563091
Nat Commun. 2018 Sep 3;9(1):3555
pubmed: 30177845
J Biophotonics. 2020 Nov;13(11):e202000125
pubmed: 32526081
Biomed Rep. 2016 Mar;4(3):263-268
pubmed: 26998261
J Lipid Res. 2013 Sep;54(9):2325-40
pubmed: 23821742
Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):346-57
pubmed: 16778562
Nat Med. 2020 Jul;26(7):1041-1043
pubmed: 32572266
J Breath Res. 2018 Jul 30;12(4):046003
pubmed: 29984709
J Breath Res. 2016 Feb 09;10(1):016007
pubmed: 26857451